Atypical Femur Fractures: 81 Individual Personal Histories
- 1 December 2012
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 97 (12) , 4324-4328
Abstract
An online voluntary association of individuals who had incurred one or more atypical femur fractures (AFFs) while taking bisphosphonates for prevention or treatment of osteoporosis provided an opportunity to collect long-term histories. Individuals from a nationwide general community completed an anonymous survey documenting their history. Within a larger cadre, cases were selected where the documentation, including fracture radiographs, verified the diagnosis based on published standards. Eighty-one of this group responded to the anonymous survey. We describe passively collected observational data only. The incidence of a large number of potential variations was determined. The mean duration of bisphosphonate treatment was 9.5 yr. Prevention was the initial indication in 68% of the subjects; 94% started on alendronate, 77% reported prodromal pain, only 16% of these were diagnosed with incident stress fractures, and 39.5% experienced a contralateral AFF from less than 1 month to 49 months after the first. Of 71 subjects with a completed first AFF, 38% reported delayed healing, 11% had a complete contralateral AFF, and 22% underwent prophylactic rodding for a contralateral stress AFF. Forty-four percent of subjects with complete AFFs were continued on a bisphosphonate after the fracture. Thirty-five percent incurred a metatarsal fracture. AFF patients experienced delayed healing, prodromal pain, and persisting risk of a contralateral and/or other fracture. Femur pain evaluation in patients on long-term bisphosphonates may facilitate early diagnosis of stress AFFs, permitting intervention, thus reducing completed and/or contralateral or other fracture risk. The details of these histories will assist in counseling regarding prognosis after an initial AFF.Keywords
This publication has 10 references indexed in Scilit:
- Increasing Occurrence of Atypical Femoral Fractures Associated With Bisphosphonate UseArchives of internal medicine (1960), 2012
- Bilateral atypical insufficiency fractures of the proximal tibia and a unilateral distal femoral fracture associated with long-term intravenous bisphosphonate therapy: a case reportJournal of Medical Case Reports, 2012
- Bisphosphonate Use and the Risk of Subtrochanteric or Femoral Shaft Fractures in Older WomenJAMA, 2011
- Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral ResearchJournal of Bone and Mineral Research, 2010
- Atypical fractures of the femur and bisphosphonate therapyBone, 2010
- A rational approach to management of alendronate-related subtrochanteric fracturesThe Journal of Bone and Joint Surgery. British volume, 2010
- Alendronate-related femoral diaphysis fracture—what should be done to predict and prevent subsequent fracture of the contralateral side?Osteoporosis International, 2009
- Stress fractures in the lower extremityEuropean Journal of Radiology, 2007
- Severely Suppressed Bone Turnover: A Potential Complication of Alendronate TherapyThe Journal of Clinical Endocrinology & Metabolism, 2005
- Suppressed Bone Turnover by Bisphosphonates Increases Microdamage Accumulation and Reduces Some Biomechanical Properties in Dog RibJournal of Bone and Mineral Research, 2000